Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 April 2023 | Story Gerda-Marié van Rooyen | Photo Two Oceans Marathon Twitter
Gerda Steyn  winning the 2023 Two Oceans Marathon
Former UFS student, Gerda Steyn, made history this weekend – she is the first woman to win the Two Oceans Ultra Marathon four consecutive times.

Kovsie alumna Gerda Steyn provided much jubilation on Saturday 15 April 2023, as she became the first woman to win the Two Oceans Marathon four consecutive times. Steyn, who represented South Africa in the 2020 Summer Olympics held in Tokyo, Japan, in 2021, improved her personal best by finishing the race 39 seconds faster than her winning time in 2022.

Shortly after her fourth win in the 56 km race, Steyn told media that the desire to inspire girls kept her motivated during the race. “I thought of all the girls watching (the race) with their parents and seeing a woman who looked like everyone else winning this big race.” The former University of the Free State (UFS) professional athlete managed an average pace of 3:45 minutes per kilometre. Steyn proved that hard work pays off, as she finished 14th at the Two Oceans Ultra Marathon in 2016. Her first-ever first place at this race was in 2018, and again in 2019 and 2022 – the marathon was cancelled in 2020 and 2021 due to the COVID-19 pandemic.

Proving that she not only has golden feet but a heart of gold too, she pledged to donate some of her bonus money towards the development of athletes living in Muizenberg shortly after she won the Two Oceans in record time in 2022. A true example of perseverance and hard work, she also won the Comrades Marathon in 2019, and finished seventh in the London Marathon in 2020. 

Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, says that Gerda is an embodiment of focus and determination. “I am so proud of her. The UFS is truly the home of champions, as can be seen by the achievements of Olympic track athletes Wayde van Niekerk, Louzanne Coetzee, and champions in many other sporting codes.”

Saturday’s Two Oceans Marathon saw Ethiopian-born Amelework Fikadu Bosho finish second in the women’s race – crossing the finish line 12 minutes after Steyn – with Carla Molinaro from Britain in the third position. Approximately 10 000 athletes entered the race, starting at the Newlands Stadium and ending on the University of Cape Town's campus.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept